At a glance
ClinicalIndex Comparison Record- ✓DSM-IV diagnosis of current marijuana abuse or dependence, confirmed by SCID-SUD
- ✓DSM-IV diagnosis of current major depressive disorder, confirmed by K-SADS
- ✓Marijuana use at least two days within the week prior to enrollment
- ✓Demonstrated adequate levels of depressive symptoms within the week prior to enrollment
- ✕DSM-IV diagnosis of bipolar disorder, schizoaffective disorder, or schizophrenia
- ✕Hypo or hyperthyroidism
- ✕Significant cardiac, neurological, or kidney impairment
- ✕Liver disease (SGOT, SGPT, or gamma-GTP greater than 3 times the normal level)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fluoxetine for Major Depressive Disorder/Cannabis Disorder in Young People
In Brief
A Phase 2 clinical trial evaluating Fluoxetine and Placebo for Depressive Disorder, Major and Cannabis Abuse. Completed, enrolled 70 participants across 1 site.
Detailed Summary
Adolescents who are diagnosed with major depressive disorder are often also diagnosed with marijuana dependence. Fluoxetine is an antidepressant medication currently used to treat young people who are diagnosed with major depressive disorder. The purpose of this study is to determine the effectiveness of fluoxetine in treating adolescents and young adults diagnosed with both major depressive disorder and marijuana dependence.
Study Details
Timeline
Interventions
Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.